Trevena is a biopharmaceutical company. Co.'s primary product, OLINVYK (oliceridine) injection, is an opioid agonist for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Co.'s product candidates include: TRV250, which is a G-protein biased delta-opioid receptor agonist as a compound with a mechanism for the treatment of acute migraine; TRV045, which is Co.'s sphingosine-1-phosphate receptor modulator that may provide a non-opioid approach to managing chronic pain; as well as TRV734, a new chemical entity targeting the same mechanism of action at the mu opioid receptor as OLINVYK. The TRVN YTD return is shown above.
The YTD Return on the TRVN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether TRVN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TRVN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|